Robust pipeline promises more options in ulcerative colitis

12 August 2022
globaldata

Industry analyst GlobalData has released new research indicating the scale of development work currently being undertaken in the ulcerative colitis space.

Ulcerative colitis (UC) is an inflammatory bowel disease in which patients experience inflammation and ulcers in the large intestine, significantly impacting quality of life.

The market for therapies is at present estimated to be worth around $7.5 billion worldwide, comprising around a tenth of revenues in immunology, with analysts forecasting steady growth in the years ahead.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology